Br J Clin Pract. 1994 Sep-Oct;48(5):231-5.
A 1-year prospective study was conducted in 475 hypercholesterolaemic men and women who received simvastatin monotherapy 10-40 mg daily for 3 months followed by additional lipid-lowering medication after this period, if necessary, to reach a target of plasma cholesterol < 5.3 mmol/l. Of these, 403 subjects completed 1 year of follow-up. By the end of the 3-month monotherapy period, the following percentage mean changes were seen (with 95% confidence intervals): total cholesterol (TC) -31% (-30 to -32%), low-density lipoprotein cholesterol -39% (-38 to -40%), triglycerides -14% (-11 to -17%) and high-density lipoprotein cholesterol +12% (+11 to +14%). These levels were maintained for the remainder of the study. When subjects with a baseline TC of 6.5-7.8 mmol/l were considered (n = 89), 42.7% achieved the target TC levels on simvastatin monotherapy alone. Additional hypolipidaemic medication had no significant impact on plasma lipid and lipoprotein levels. Simvastatin was well tolerated both as monotherapy and in combination.
对475名高胆固醇血症男性和女性进行了一项为期1年的前瞻性研究，这些患者每日接受10 - 40毫克辛伐他汀单药治疗3个月，此后必要时加用其他降脂药物，以达到血浆胆固醇<5.3毫摩尔/升的目标。其中，403名受试者完成了1年的随访。在3个月的单药治疗期结束时，观察到以下平均变化百分比（95%置信区间）：总胆固醇（TC）-31%（-30至-32%），低密度脂蛋白胆固醇-39%（-38至-40%），甘油三酯-14%（-11至-17%），高密度脂蛋白胆固醇+12%（+11至+14%）。这些水平在研究的剩余时间内保持稳定。当考虑基线TC为6.5 - 7.8毫摩尔/升的受试者时（n = 89），仅辛伐他汀单药治疗就有42.7%的受试者达到了目标TC水平。额外的降血脂药物对血浆脂质和脂蛋白水平没有显著影响。辛伐他汀作为单药治疗或联合治疗时耐受性良好。
